The firm will make its artificial intelligence-based Lunit SCOPE IO platform available to SITC member researchers.

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

The Department of Health and Social Care is gauging whether AI technology can increase the number of patients screened by each radiologist.

Thirty patients have received the gene therapy within a clinical trial and early-access program, and the foundation also hopes to seek approval in the US.

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

The proposal, purported to save $83 billion over a decade, is a "dagger in the heart of all patient advocacy nonprofits," said the head of a cancer patient support group.

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

The FDA has offered positive feedback on possible paths forward for accelerated or traditional approval of FLT201 using data from a single-arm study.

NEW YORK – UniQure on Monday said it will begin treating a second cohort of Fabry disease patients with a higher dose of its AMT-191 gene therapy in a Phase I/IIa trial. The decision to advance the ...